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Purpose: Preoperative partial breast irradiation (PBI) has the potential to induce tumor regression. We evaluated the differ-
ences in the numbers of preirradiation tumor infiltrating lymphocytes (TILs) between responders and nonresponders after
preoperative PBI in low-risk patients with breast cancer. Furthermore, we evaluated the change in number of TILs before
and after irradiation.
Methods and Materials: In the prospective ABLATIVE study, low-risk patients with breast cancer underwent treatment with
single-dose preoperative PBI (20 Gy) to the tumor and breast-conserving surgery after 6 or 8 months. In the preirradiation
diagnostic biopsy and postirradiation resection specimen, numbers of TILs in 3 square regions of 450  450 mm were
counted manually. TILs were visualized with CD3, CD4, and CD8 immunohistochemistry. Differences in numbers of pre-
irradiation TILs between responders and nonresponders were tested using Mann-Whitney U test. Responders were defined
as pathologic complete or near-complete response, and nonresponders were defined “as all other response.” Changes in
numbers of TILs after preoperative PBI was evaluated with the Wilcoxon signed rank test.
Results: Preirradiation tissue was available from 28 patients, postirradiation tissue from 29 patients, resulting in 22 pairs of
preirradiation and postirradiation tissue. In these 35 patients, 15 had pathologic complete response (43%), 11 had a near-
complete response (31%), 7 had a partial response (20%), and 2 had stable disease (6%). The median numbers of CD3þ TILs,
CD4þ TILs, and CD8þ TILs in the preirradiation tumor tissue were 49 (interquartile range [IQR], 36-80), 45 (IQR, 28-57),
and 19 (IQR, 8-35), respectively. The number of preirradiation TILs did not differ significantly between responders and
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nonresponders. The median numbers of CD3þ TILs, CD4þ TILs, and CD8þ TILs in postirradiation tumor tissue were 17
(IQR, 13-31), 26 (IQR, 16-35), and 7 (IQR, 5-11), respectively.
Conclusions: After preoperative PBI in this limited cohort, the number of TILs in tumor tissue decreased. No differences in
numbers of preirradiation TILs between responders and nonresponders were observed.  2020 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction
Preoperative partial breast irradiation (PBI) has the poten-
tial to induce tumor regression in patients with breast
cancer.1 In our previous study (ABLATIVE, Clinical-
Trials.gov identifier: NCT06863301) of a single dose (20
Gy) of preoperative PBI, 15 of 36 low-risk patients with
breast cancer resulted in a pathologic complete response
after an interval of 6 to 8 months between irradiation and
breast-conserving surgery2. Complete tumor regression
after preoperative PBI could allow omission of breast sur-
gery in future patients with no clinical evidence of residual
disease.3,4 To assess which patients will achieve or have
achieved pathologic complete response (pCR), adequate
response assessment is eminent.
Response assessment during standard preoperative sys-
temic treatment currently consists of magnetic resonance
imaging or 18F-fluorodeoxyglucose positron emission
tomographyecomputed tomography (PET/CT), or both.
Several studies have shown that the predictive value of both
magnetic resonance imaging and PET/CT for pathologic
response is insufficient to identify patients in whom surgery
after preoperative systemic treatment (PST) can be
omitted.5-7
To increase the predictive value of response assessment
after preoperative systemic treatment or radiation therapy,
in the assessment of immune infiltrates, so-called tumor
infiltrating lymphocytes (TILs) have been proposed as a
biomarker.8-11 Increased numbers of TILs in resection
specimens of patients with triple-negative breast cancer
treated with PST have been associated with improved
outcome, such as disease-free survival and overall sur-
vival.8 The explanation for the association between the
number of TILs and improved clinical outcome lies within
the activation of the immune system after PST, which can
result in the inhibition of tumor growth and induction of
immunogenic cell death.12-14 The number of TILs can be
evaluated as a representation of the activation of the im-
mune system. However, TILs cannot be identified in all
patients, thus complicating the investigation of TILs as a
biomarker.15,16 The important types of TILs in patients with
breast cancer whom we studied are CD3þ TILs, CD4þ
TILs, and CD8þ TILs. The expression of CD3 is crucial for
the activation of T cells in an antitumor response, activation
of CD4 directly activates CD8þ T cells and leads to the
production of tumor necrosis factor-a.17-19 CD8 is
expressed on cytotoxic T cells, and it increases sensitivity
of the T cell to the presented antigen.17,20
In this study, we assessed TILs before and after preop-
erative PBI in low-risk patients, and we evaluated the dif-
ferences in numbers of preoperative TILs between




The preirradiation diagnostic core needle biopsies and
postirradiation resection specimens of low-risk patients
with luminal breast cancer included in the single arm
ABLATIVE trial of single-dose preoperative PBI were
evaluated2. The ABLATIVE trial was approved by the
institutional review board of the UMC Utrecht, the
Netherlands, and registered at ClinicalTrials.gov
(NCT06863301). After providing informed consent, pa-
tients with unifocal ductal or mucinous invasive breast
cancer with a maximum diameter of 3 cm, ER-positive and
HER2-negative tumor, a negative sentinel lymph node bi-
opsy, and no indication for preoperative chemotherapy or
immunotherapy were enrolled. Participating patients
received a single ablative radiation therapy dose of 20 Gy
to the tumor and 15 Gy to the breast tissue within 2 cm of
the tumor. Patients underwent breast-conserving surgery
after an interval of 6 or 8 months after preoperative PBI.
The pathologic response after preoperative PBI was
assessed using the European Society of Breast Cancer
Specialists criteria according to the national guidelines.21,22
The possible responses were (1) pCR, (2) near pCR (<10%
residual disease), (3) partial response (10%-50% residual
disease), (4) stable disease (>50% residual disease), or (5)
no evidence of response. Thirty-six women were included
in the clinical trial, but for 1 patient no additional pre-
irradiation and postirradiation tumor tissue could be
retrieved. For 22 patients, both the diagnostic biopsy and
the resection specimen were available; for 6 patients, only
the preirradiation diagnostic biopsy was available; and for 7
patients, only the postirradiation resection specimen was
available.
Assessment of tumor infiltrating lymphocytes
Consecutive slides of 4 mm were obtained from formalin-
fixed paraffin-embedded tissue blocks of the diagnostic
tumor biopsy and resection specimens. These slides were
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prepared for immunohistochemical (IHC) staining for CD3,
CD4, and CD8, using rabbit anti-CD3 polyclonal antibody
(DAKO, A0452, dilution 1:100; Glostrup, Denmark), rabbit
anti-CD4 monoclonal antibody (Cellmarque, 104R-16,
dilution 1:20; Rocklin, CA), and mouse anti-CD8 mono-
clonal antibody (DAKO, M7103, dilution 1:100), respec-
tively. If available, an additional slide was stained with
hematoxylin and eosin (HE). All slides were digitalized
with a NanoZoomer-XR digital slide scanner (Hamamatsu,
Hamamatsu City, Japan) at original magnification 40.
The preirradiation and postirradiation slides were
assessed separately. The clinical information and histo-
pathologic reports were available during annotation of
representative tumor areas. This annotation was performed
by a researcher (M.D.) and an experienced breast
pathologist on HE-stained slides and then copied to the
IHC-stained slides. When no HE-stained slide was avail-
able, the first annotation was performed on CD3-stained
slides. The tumor was annotated on the preirradiation
slides, and the irradiated tumor and area of tumor regres-
sion were annotated on the postirradiation slides. The
irradiated tumor and area of regression were identified by
reactive changes, such as scarlike fibrosis and iron-loaded
macrophages. If distinction between the area of regression
and surrounding stroma was not clear, stroma with the same
density as the definitive area of regression was included in
the annotation. After tumor or area of regression annota-
tion, 3 square fields of 450  450 mm were selected
randomly in all slides, and the number of TILs was quan-
tified manually by dotting each lymphocyte in these fields.
TIL assessment was performed blinded to clinical infor-
mation and histopathologic reports.
Statistical analysis
Pathologic response was grouped to responders (defined as
pCR and near-pCR) and nonresponders (defined as partial
response, stable disease, and no evidence of response). The
number of TILs was expressed as the mean of the 3 selected
squares and calculated for both the diagnostic biopsy and
resection specimen. The number of preirradiation and
postirradiation TILs and change in number of TILs were
presented using median and interquartile range (IQR).
Differences in numbers of preirradiation TILs between re-
sponders and nonresponders were tested using Mann-
Whitney U test. Differences in numbers of TILs between
preirradiation and postirradiation were tested using Wil-
coxon signed rank test. Statistical tests were 2-sided and
performed at a significance level of 0.05. Statistical anal-
ysis was performed using IBM SPSS Statistics for Win-
dows, version 25 (IBM, Armonk, NY).
Results
Of the 35 analyzed low-risk patients with breast cancer, the
median age was 64 years (range, 51-78 years) and the
median tumor size was 13 mm (range, 5-20 mm; Table 1).
Of the total of 35 patients, 15 patients achieved pCR (43%),
11 patients achieved near pCR (31%), 7 patients achieved
partial response (20%), and 2 patients had stable disease
(6%). Of the 28 preirradiation samples, 13 patients ach-
ieved pCR (46%), 9 patients achieved near pCR (32%), 5
patients achieved partial response (18%), and 1 patient had
stable disease (4%). Of the 29 postirradiation samples, 12
patients achieved pCR (41%), 10 patients achieved near
pCR (35%), 6 patients achieved partial response (21%), and
1 patient had stable disease (3%). In some cases, only the
preirradiation (6 cases) or postirradiation (7 cases) slides
were available, because no tumor material was left for IHC
staining after the necessary clinical pathology assessment.
In 5 cases the preirradiation slide did not contain enough
tumor material to select 3 square fields of 450  450 mm;
therefore, fewer fields were selected. Because of techni-
cally inadequate staining, not all IHC staining could be
assessed for every case.
In the preirradiation slides the median number of CD3þ
TILs was 49 (IQR, 36-80), of CD4þ TILs 45 (IQR, 28-57),
and of CD8þ TILs 19 (IQR, 8-35; Fig. 1). For responders
and nonresponders, the median number of CD3þ was 57
and 45 (P Z .74), the median number of CD4þ 42 and 50
(P Z .98), and the median number of CD8þ was 19 and 16
(P Z .48), respectively (Fig. 2). In the postirradiation
Table 1 Patient and tumor characteristics of 35 low-risk
patients with breast cancer studied for the association be-
tween tumor infiltrating lymphocytes and pathologic response
after preoperative partial breast irradiation
Characteristics Data
Median tumor diameter, mm
(range)*
13 (5-20)






Not assessabley 1 (3)
Histology type, n (%)
Ductal 34 (97)
Mucinous 1 (3)














No response 0 (0)
* Tumor diameter as assessed on magnetic resonance imaging.
y Not assessable because of small tumor biopsy.
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slides, the median number of CD3þ, CD4þ, and CD8þ
TILs was 17 (IQR, 13-31), 26 (IQR, 16-35), and 7 (IQR, 5-
11), respectively (Fig. 1).
In the 22 patients in whom both the preirradiation and
postirradiation number of TILS could be assessed, a sta-
tistically significant decrease in TILs was observed. In
these 22 patients, the median preirradiation number of
CD3þ TILs was 45 (IQR, 33-79), and median post-
irradiation number of TILs 16 (IQR, 12-22), for CD4þ TILs
the numbers were 44 (IQR, 30-55) and 25 (IQR, 13-35),
respectively, and for CD8þ TILs the numbers were 17
(IQR, 7-37) and 6 (IQR, 5-9), respectively. A median
decrease of 69% (P Z .002) was observed for CD3þ, a
median decrease of 27% (P Z .003) was observed for
CD4þ, and a median decrease of 74% (P Z .004) was
observed for CD8þ.
Discussion
TILs could be clearly identified in all low-risk patients with
breast cancer, both before and after irradiation (Fig. 3). We
observed no differences in the number of preirradiation
TILs between responders and nonresponders.
We observed a large range in the number of preirradiation
and postirradiation TILs, with the largest range in the number
of CD3þ lymphocytes. Similarly, a large range in pretreat-
ment TILs in patients with breast cancer treated with PST
has been reported. Denkert et al23 evaluated the percentage
of intratumoral and stromal TILs before PST of cT1-3N0-
2M0 breast cancer.23 In core biopsy specimens of 1058 pa-
tients, they observed tumors without any TILs and tumors
with >50% TILs. In a study that evaluated CD8þ TILs in the
resection specimen of 1334 patients with breast cancer (pT1-
2N0-2M0) after primary surgery within the Nottingham
Tenovus Primary Breast Carcinoma series, a median of 11
TILs was observed in a field of 0.28 mm2 (IQR, 2-34).20 This
number of TILs is comparable to the median of 19 CD8þ
TILs (IQR, 8-35) in the preirradiation tumor tissue within our
study, despite the low-risk patients in our study and in
contrast to the more advanced disease in the Nottingham
series. Kovács et al11 evaluated a more comparable group of
patients with early-stage breast cancer; they found that pa-
tients with luminal A and B type tumors had the lowest
percentage of TILs.
The observed decrease in number of TILs after preoper-
ative irradiation was higher than in previous studies of pre-
operative systemic treatment of locally advanced and
inflammatory breast cancer.15,24 In addition to the different
treatment approach, this could be attributed to the lower
number of preirradiation TILs and longer interval of up to 8
months between irradiation and postirradiation assessment of
TILs in our study. This approach resulted in tumor regression
after an ablative dose of radiation therapy, including fewer
vital tumor cells for immune cells to respond to.
Pretreatment TILs have been shown to be a significant
predictor of pathologic complete response and prolonged
survival after PST in breast cancer.10,20,23 In our small se-
ries, we did not observe an association between pretreat-
ment TILs and pathologic response. Most of the affirmative
studies on TILs during PST included patients with a more
advanced disease stage than in the present study. In addi-
tion, many studies reported the predictive value of pre-
treatment TILs for response to PST in triple-negative breast
cancer, and not in ERþ breast cancers.25-27 Moreover, all
cases in our study, except for one, had a Bloom-Richardson
grade 1 or 2 tumor. Low-grade tumors have been reported



















N = 26 N = 28 N = 27 N = 28 N = 29N = 29
Fig. 1. Numbers of preirradiation and postirradiation (6 to 8 months after irradiation) tumor-infiltrating lymphocytes of
patients with breast cancer treated with preoperative partial breast irradiation. )P < .05 for difference with preirradiation
number of tumor-infiltrating lymphocytes.
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have,11,28 which could also explain why we were not able to
demonstrate an association between pretreatment TILs and
pathologic response.
A strength of the current study is the availability of both
preirradiation and postirradiation slides for the same pa-
tients, enabling us to assess the effect of irradiation on the
number of TILs. Second, the number of TILS was assessed
through several different IHC stainings that highlight TIL
subtypes and that can help us in understanding the contri-
bution of the different types of immune cells to respond to
preoperative PBI. Although a significant decrease in TILs
after preoperative PBI was observed, we could not differ-
entiate between responders and nonresponders using the
number of preoperative TILs, an important step in the ul-
timate treatment de-escalation (ie, omission of surgery).
Nevertheless, it is remarkable that even after the long in-
terval of 6 to 8 months after preoperative PBI, TILs were
stills observed in all cases. In several publications, TILs
were not observed in cases achieving pCR after PST.15,16
The TILs international working group has recently
encouraged the evaluation of posttreatment TILs in a
research setting, especially in the case of pCR.13
A limitation of the present study is that it was designed
as a feasibility study for the novel treatment option of
single-dose preoperative PBI; therefore, it was not powered
on finding predictors for treatment response. Furthermore,
not all biopsy and resection specimens could be retrieved
and evaluated, which decreased the already limited sample
size. However, we assume that the missing samples were
not associated with the pathologic response, because the
percentage of responders and nonresponders was not
different between the entire group of patients, the group of
patients with a preirradiation sample available, and the
group of patients with a postirradiation sample available.
Therefore, the missing samples are presumably at random,
and they will not affect the interpretation of our results.
Nonetheless, a larger number of available slides could have
improved the differentiation between responders and non-
responders, and we recommend further evaluation of TILs
as a biomarker in future larger cohorts. Furthermore, as the
preirradiation biopsy was performed for diagnostic pur-
poses, only a single biopsy specimen was taken. Only the
single biopsy specimen could be assessed, which could
have led to overestimation or underestimation of the
number of TILs, because no purposeful sampling has been
performed.29 The present study could also have benefitted
from additional biopsies of the irradiated tumor a few
weeks after irradiation, to better assess the acute immune
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Fig. 2. Numbers of preirradiation and postirradiation (6 to 8 months after irradiation) tumor-infiltrating lymphocytes in
low-risk patients with breast cancer treated with preoperative partial breast irradiation according to pathologic response. No
significant differences in numbers of preirradiation tumor-infiltrating lymphocytes between responders and nonresponders
were found.
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response because the acute response has faded at 6 to 8
months after preoperative PBI. It could be hypothesized
that tumors with a more extensive acute cellular immune
response have a higher chance of achieving pCR, which
might be better assessable 6 to 8 weeks after irradiation
than the currently used 6 to 8 months. These additional
biopsies were not performed to avoid imposing this addi-
tional burden on participating patients. Other possible
biomarkers for the prediction of pathologic response after
preoperative PBI that could be further investigated are
magnetic resonance imaging, including functional imaging,
and circulating tumor DNA.30-32 With all these possible
biomarkers, a large patient cohort will be necessary to
differentiate between responders and nonresponders, as we
expect only subtle differences in these low-risk patients.
Conclusion
TILs could be determined in tumor tissue of low-risk pa-
tients before and after an ablative dose of preoperative PBI
using IHC staining. In this limited cohort, a statistically
significant decrease in TILs was observed after irradiation.
No differences in numbers of preirradiation TILs between
responders and nonresponders were observed in this small
group of low-risk patients with breast cancer.
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